Andere talen Organon & Co.

Aandelen

OGN

US68622V1061

Beurs gesloten - Nyse Andere beurzen 22:00:02 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,55 ^USD	+0,71%		+4,10%	+28,64%

09/04	ORGANON & CO. : Morgan Stanley is Neutraal over het aandeel	ZM
08/04	Shanghai Henlius Biotech Denosumab Biosimilar HLX14 haalt eindpunt	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	08/04
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	08/04
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires	08/04
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08/04
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	08/04
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	08/04
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	20/03
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	08/03
Philips : une nouvelle directrice financière en octobre	28/02
New York attorney general urges stronger safety warning on asthma drug Singulair	23/02
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary	21/02
Organon's Hadlima Chosen by VA as Substitute for Humira	20/02
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies	20/02
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	15/02
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	15/02
Organon: Q4 Earnings Snapshot	15/02
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Organon & Co.

Aandelen

OGN

US68622V1061

Andere talen

Filters